Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Nasopharyngeal carcinoma (NPC) pathogenesis involves complex molecular mechanisms.
• The role of FOXO1 as a tumor suppressor in NPC requires further elucidation.
• Understanding therapeutic targets is crucial for improving NPC treatment outcomes.

Purpose of the Study:

• To investigate the novel molecular mechanisms of FOXO1's tumor-suppressive function in NPC.
• To identify how FOXO1 regulates tumor stemness, metastasis, and chemosensitivity.
• To explore the therapeutic potential of cinobufotalin (CB) in enhancing NPC treatment.

Main Methods:

• In vitro and in vivo studies using NPC cell lines and animal models.
• Analysis of molecular pathways including GSK3β/β-catenin/TCF4, PI3K/AKT/c-Myc/P53/miR-133a-3p.
• Investigation of FOXO1 interaction with MYH9 and its downstream effects.
• Assessment of cinobufotalin's efficacy in modulating these pathways and enhancing cisplatin (DDP) chemosensitivity.
• Correlation analysis of FOXO1 and MYH9 expression with clinical outcomes in NPC patients.

Main Results:

• FOXO1 suppresses NPC stemness and metastasis, and sensitizes cells to DDP.
• FOXO1 induces miR-200b expression via the GSK3β/β-catenin/TCF4 network, reducing ZEB1 and epithelial-mesenchymal transition (EMT).
• FOXO1 suppresses MYH9 expression, which in turn increases GSK3β stability and activity, further enhancing the miR-200b network.
• Cinobufotalin enhances FOXO1-mediated DDP chemosensitivity by reducing MYH9 expression.
• Low FOXO1 and high MYH9 expression correlate with poor survival in NPC patients.

Conclusions:

• FOXO1 acts as a crucial tumor suppressor in NPC by regulating stemness and EMT.
• The FOXO1-MYH9 axis is a key determinant of NPC progression and chemosensitivity.
• Cinobufotalin shows promise as a therapeutic agent to potentiate DDP treatment in NPC by targeting the FOXO1-MYH9 pathway.